ALK-Abelló — Board/Management Information 2022

Nov 30, 2022

COMPANY RELEASE No 18/2022

ALK

Management change at ALK

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Søren Jelert, Executive Vice President, CFO and member of the Board of Management, has decided to resign his position to join a company in another sector and will expectedly leave ALK on 31 May 2023.

Chairman of the Board of Directors, Anders Hedegaard, and President & CEO, Carsten Hellmann said: "We would like to offer our sincere thanks to Søren for his pivotal role in ALK's transformation over the past five years. We wish him the best of luck in his future career."

A search for a new CFO has been initiated.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, mobile +45 3050 2014

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Company release No 18/2022 – 30 November 2022

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk.net

Tel +45 4574 7576 – CVR No 63 71 79 16 – LEI code: 529900SGCREUZCZ7P020